Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189486 | 0.86 | ADRB3 (0.44) | ADRB3ADRA1AKDM4EMEN1KMT2A | |
| SCHEMBL31264968 | 0.84 | ADRB3 (0.43) | ADRB3ADRA1AKDM4EMEN1KMT2A | |
| SCHEMBL31119161 | 0.83 | ADRB3 (0.40) | ADRB3 | |
| SCHEMBL16188164 | 0.81 | ADRB3 (0.41) | ADRB3F2F7F3ALDH1A1 | |
| SCHEMBL10189678 | 0.81 | ADRB3 (0.41) | ADRB3F2F7F3KDM4E | |
| SCHEMBL15160576 | 0.73 | MAP3K5 (0.33) | ADRB3ADRA1A | |
| SCHEMBL16590483 | 0.71 | ADRB3 (0.34) | ADRB3 | |
| SCHEMBL31565052 | 0.70 | PREP (0.37) | F2F7F3ALDH1A1 | |
| SCHEMBL11107898 | 0.68 | MGLL (0.31) | ADRB3KMT2A | |
| SCHEMBL4186661 | 0.67 | CYP3A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118078835-A | Therapeutic agent for nocturnal frequency | 杏林制药株式会社 | 2024-05-28 | — | — | CN | claimed |
| CN-118078835-A | Therapeutic agent for nocturnal frequency | 杏林制药株式会社 | 2024-05-28 | — | — | CN | disclosed |
| CN-118078835-A | Therapeutic agent for nocturnal frequency | 杏林制药株式会社 | 2024-05-28 | — | — | CN | disclosed |
| CN-117402117-B | Preparation method of 4-pyrimidinone derivative | 南京威凯尔生物医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117695286-A | Treatment of overactive bladder with velbegron | 住友制药(苏州)有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117695287-A | Treatment of overactive bladder with velbegron | 住友制药(苏州)有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117402117-A | Preparation method of 4-pyrimidinone derivative | 南京威凯尔生物医药科技有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230027066-A1 | USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER | UROVANT SCIENCES GMBH (CH) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027066-A1 | USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER | BDKRB2, TACR1, AVPR1B | ADRB3 50/4885F2 3363/4885F7 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.